Inflammation‑based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl‑world Data project 02 (TREAD 02) DOI Open Access
Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu

et al.

Molecular and Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(6)

Published: Oct. 3, 2024

In addition to blood test data, inflammation-based prognostic markers have been used predict the prognosis of various types cancer. However, several these previous studies may be outdated, as they were conducted prior widespread adoption immune checkpoint inhibitors, leading limited reports on their efficacy. The present study aimed assess accuracy different in patients with advanced or recurrent gastric cancer undergoing nivolumab monotherapy salvage-line chemotherapy. a retrospective cohort across Japan, total 159 who treated between September 2017 and March 2020 selected. Blood data collected within 14 days start chemotherapy 17 evaluated. Cox regression analysis was performed using all patient background factors. Subsequently, model selection backward elimination based Akaike information criterion (AIC) obtain effective factors which could assessed for impact survival. For each marker, magnitude survival rate, after adjusting factors, concordance AIC analyses. A (female, 30.2%; median age, 70 years) included study. Most received platinum, fluoropyrimidine taxane treatment, three lines systemic therapy. With follow-up 3.3 months (95% CI, 2.5-3.8), overall time treatment failure 3.8 3.3-4.5) 1.8 1.8-2.3), respectively. Amongst analyzed, modified Glasgow score (mGPS) classed most useful factor that affected rate patients. Real-world showed mGPS, an had strongest correlation receiving monotherapy. registered clinical trial UMIN Clinical Trial Registry (http://www.umin.ac.jp/ctr/index.htm) under registration number UMIN000050590 15th 2023.

Language: Английский

Inflammation‑based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl‑world Data project 02 (TREAD 02) DOI Open Access
Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu

et al.

Molecular and Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(6)

Published: Oct. 3, 2024

In addition to blood test data, inflammation-based prognostic markers have been used predict the prognosis of various types cancer. However, several these previous studies may be outdated, as they were conducted prior widespread adoption immune checkpoint inhibitors, leading limited reports on their efficacy. The present study aimed assess accuracy different in patients with advanced or recurrent gastric cancer undergoing nivolumab monotherapy salvage-line chemotherapy. a retrospective cohort across Japan, total 159 who treated between September 2017 and March 2020 selected. Blood data collected within 14 days start chemotherapy 17 evaluated. Cox regression analysis was performed using all patient background factors. Subsequently, model selection backward elimination based Akaike information criterion (AIC) obtain effective factors which could assessed for impact survival. For each marker, magnitude survival rate, after adjusting factors, concordance AIC analyses. A (female, 30.2%; median age, 70 years) included study. Most received platinum, fluoropyrimidine taxane treatment, three lines systemic therapy. With follow-up 3.3 months (95% CI, 2.5-3.8), overall time treatment failure 3.8 3.3-4.5) 1.8 1.8-2.3), respectively. Amongst analyzed, modified Glasgow score (mGPS) classed most useful factor that affected rate patients. Real-world showed mGPS, an had strongest correlation receiving monotherapy. registered clinical trial UMIN Clinical Trial Registry (http://www.umin.ac.jp/ctr/index.htm) under registration number UMIN000050590 15th 2023.

Language: Английский

Citations

2